126 related articles for article (PubMed ID: 38072744)
1. Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment.
Cuenin M; Salleron J; Peiffert D; Meknaci É; Gallet P; Abushama Y; Py JF; Renard S
Cancer Radiother; 2024 Apr; 28(2):145-151. PubMed ID: 38072744
[TBL] [Abstract][Full Text] [Related]
2. High dose-rate versus low dose-rate brachytherapy for lip cancer.
Ghadjar P; Bojaxhiu B; Simcock M; Terribilini D; Isaak B; Gut P; Wolfensberger P; Brömme JO; Geretschläger A; Behrensmeier F; Pica A; Aebersold DM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1205-12. PubMed ID: 22099044
[TBL] [Abstract][Full Text] [Related]
3. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
5. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
[TBL] [Abstract][Full Text] [Related]
6. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments.
Visser AG; van den Aardweg GJ; Levendag PC
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):497-505. PubMed ID: 8567354
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.
Mattei P; Chabrillac E; Cabarrou B; Dupret-Bories A; Vergez S; Sarini J; Lopez R; Piram L; Brun T; Modesto A
Strahlenther Onkol; 2022 Feb; 198(2):150-158. PubMed ID: 34786604
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and tolerance of pulsed dose rate interstitial brachytherapy.
de Pree C; Popowski Y; Weber D; Nouet P; Rouzaud M; Kurtz JM
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):971-6. PubMed ID: 10192342
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma.
Sarkaria JN; Petereit DG; Stitt JA; Hartman T; Chappell R; Thomadsen BR; Buchler DA; Fowler JF; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):75-82; discussion 247. PubMed ID: 8083131
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers.
Varela Cagetti L; Zemmour C; Salem N; Minsat M; Ferrè M; Mailleux H; Giovaninni M; Lelong B; De Chaisemartin C; Ries P; Poizat F; Tallet A; Moureau-Zabotto L
Brachytherapy; 2019; 18(6):814-822. PubMed ID: 31515067
[TBL] [Abstract][Full Text] [Related]
13. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
[TBL] [Abstract][Full Text] [Related]
14. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
15. HDR and LDR Brachytherapy in the Treatment of Lip Cancer: the Experience of the Catalan Institute of Oncology.
Ayerra AQ; Mena EP; Fabregas JP; Miguelez CG; Guedea F
J Contemp Brachytherapy; 2010 Mar; 2(1):9-13. PubMed ID: 28031737
[TBL] [Abstract][Full Text] [Related]
16. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
17. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
18. Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate.
Levendag PC; Schmitz PI; Jansen PP; Senan S; Eijkenboom WM; Sipkema D; Meeuwis CA; Kolkman-Deurloo IK; Visser AG
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):497-506. PubMed ID: 9231672
[TBL] [Abstract][Full Text] [Related]
19. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer.
Inoue T; Inoue T; Teshima T; Murayama S; Shimizutani K; Fuchihata H; Furukawa S
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1201-4. PubMed ID: 8985043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
